Larotrectinib for the treatment of TRK fusion solid tumors.

Manju L. Prasad, Monika Vyas, Matthew J. Horne, Renu K. Virk, Raffaella Morotti, Zongzhi Liu, Giovanni Tallini, Marina N. Nikiforova, Emily R. Christison-Lagay, Robert Udelsman, Catherine A. Dinauer, Yuri E. Nikiforov, NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. ,vol. 122, pp. 1097- 1107 ,(2016) , 10.1002/CNCR.29887

Sarah Tannenbaum-Dvir, Julia L. Glade Bender, Alanna J. Church, Katherine A. Janeway, Marian H. Harris, Mahesh M. Mansukhani, Peter L. Nagy, Stuart J. Andrews, Vundavalli V. Murty, Angela Kadenhe-Chiweshe, Eileen P. Connolly, Andrew L. Kung, Filemon S. Dela Cruz, Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma Cold Spring Harb Mol Case Stud. ,vol. 1, ,(2015) , 10.1101/MCS.A000471

John P Russell, Daniel J Powell, Mary Cunnane, Angela Greco, Giuseppe Portella, Massimo Santoro, Alfredo Fusco, Jay L Rothstein, The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene. ,vol. 19, pp. 5729- 5735 ,(2000) , 10.1038/SJ.ONC.1203922

Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena, NTRK gene fusions as novel targets of cancer therapy across multiple tumour types ESMO Open. ,vol. 1, ,(2016) , 10.1136/ESMOOPEN-2015-000023

Ramamoorthy Nagasubramanian, Julie Wei, Paul Gordon, Jeff C. Rastatter, Michael C. Cox, Alberto Pappo, Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatric Blood & Cancer. ,vol. 63, pp. 1468- 1470 ,(2016) , 10.1002/PBC.26026

S Saußele, J Richter, A Hochhaus, F-X Mahon, The concept of treatment-free remission in chronic myeloid leukemia Leukemia. ,vol. 30, pp. 1638- 1647 ,(2016) , 10.1038/LEU.2016.115

Krittiya Korphaisarn, Scott Kopetz, BRAF-Directed Therapy in Metastatic Colorectal Cancer The Cancer Journal. ,vol. 22, pp. 175- 178 ,(2016) , 10.1097/PPO.0000000000000189

David S. Hong, Anna F. Farago, Marcia S. Brose, Howard A. Burris, Afshin Dowlati, Todd M. Bauer, Matthew Taylor, Alice T. Shaw, Adriana Estrada-Bernal, Anh T. Lee, Nisha Nanda, Michael C. Cox, Robert C. Doebele, Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions Cancer Research. ,vol. 76, ,(2016) , 10.1158/1538-7445.AM2016-CT008

Dean Pavlick, Alexa B. Schrock, Denise Malicki, Philip J. Stephens, Dennis J. Kuo, Hyunah Ahn, Brian Turpin, Justin M. Allen, Mark Rosenzweig, Kamran Badizadegan, Jeffrey S. Ross, Vincent A. Miller, Victor Wong, Siraj M. Ali, Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatric Blood & Cancer. ,vol. 64, ,(2017) , 10.1002/PBC.26433

Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore-Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann D. Johnson, Rupal Patel, David Luo, Edna Chow-Maneval, Zachary Hornby, Pratik S. Multani, Alice T. Shaw, Filippo G. De Braud, Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery. ,vol. 7, pp. 400- 409 ,(2017) , 10.1158/2159-8290.CD-16-1237